轻型非致残性急性缺血性卒中的双联抗血小板治疗比较:贝叶斯网络荟萃分析
该贝叶斯固定效应网络荟萃分析纳入5项随机临床试验、28 148例患者,其中22 203例(78.9%)为轻型卒中(NIHSS≤5),比较发病24小时内启动的不同双联抗血小板方案。主要终点为90天复发性缺血性卒中:阿司匹林联合替格瑞洛(NNT 40;95% CI 31-64)与阿司匹林联合氯吡格雷(NNT 58;95% CI 39-136)均优于单用阿司匹林;两种双联方案大出血风险均高于单用阿司匹林(阿司匹林联合替格瑞洛的NNH为284;95% CI 108-1715,阿司匹林联合氯吡格雷的NNH为330;95% CI 118-3430),但均未增加出血性卒中或死亡风险。在未排除CYP2C19功能缺失等位基因时,阿司匹林联合替格瑞洛成为最优治疗的概率最高(SUCRA 0.94)。对于高危TIA,阿司匹林联合替格瑞洛与阿司匹林联合氯吡格雷的优越性未被证实。
要点
- 轻型卒中(NIHSS≤5)发病24小时内启动双联抗血小板:阿司匹林联合替格瑞洛预防90天复发性缺血性卒中NNT 40(95% CI 31-64),阿司匹林联合氯吡格雷NNT 58(95% CI 39-136),均优于单用阿司匹林。
- 大出血风险:阿司匹林联合替格瑞洛NNH 284(95% CI 108-1715),阿司匹林联合氯吡格雷NNH 330(95% CI 118-3430),均高于单用阿司匹林;两者均未增加出血性卒中或死亡风险。
- 在未排除CYP2C19功能缺失等位基因的轻型卒中患者中,阿司匹林联合替格瑞洛成为最优治疗的概率为94%(SUCRA 0.94)。
- 高危TIA:阿司匹林联合替格瑞洛成为最优治疗的概率为60%(SUCRA 0.60),阿司匹林联合氯吡格雷为40%(SUCRA 0.40),两者均非最优但均优于单用阿司匹林;阿司匹林联合替格瑞洛相对于阿司匹林联合氯吡格雷的优越性未被证实。
适用人群与场景
- 发病24小时内的轻型卒中患者,轻型卒中定义为美国国立卫生研究院卒中量表(NIHSS)评分≤5分。
- 高危TIA患者(次要分析人群)。
诊断标准与关键阈值
- 轻型卒中定义:美国国立卫生研究院卒中量表(NIHSS)评分≤5分。
- 纳入标准:发病24小时内启动双联抗血小板治疗的随机临床试验。
研究设计与关键结果
- 研究类型:贝叶斯固定效应网络荟萃分析,纳入5项随机临床试验,共28 148例患者,其中22 203例(78.9%)为轻型卒中;轻型卒中患者中13 995例(63.0%)在双联抗血小板组,8208例(37.0%)在阿司匹林(乙酰水杨酸)组。
- 主要终点(90天复发性缺血性卒中):阿司匹林联合替格瑞洛NNT 40(95% CI 31-64),阿司匹林联合氯吡格雷NNT 58(95% CI 39-136),均优于单用阿司匹林;阿司匹林联合替格瑞洛成为最优治疗的概率为94%(SUCRA 0.94)。
- 大出血:阿司匹林联合替格瑞洛NNH 284(95% CI 108-1715),阿司匹林联合氯吡格雷NNH 330(95% CI 118-3430),均高于单用阿司匹林;两种双联方案均未增加出血性卒中或死亡风险。
- 高危TIA:阿司匹林联合替格瑞洛成为最优治疗的概率为60%(SUCRA 0.60),阿司匹林联合氯吡格雷为40%(SUCRA 0.40),两者均非最优,但均优于单用阿司匹林;阿司匹林联合替格瑞洛相对于阿司匹林联合氯吡格雷的优越性未被证实。
证据类型、等级与局限
- 证据类型:贝叶斯固定效应网络荟萃分析,纳入5项随机临床试验。
- 检索PubMed截至2023年11月4日发表的随机临床试验,并补充作者和/或机构提供的未发表轻型卒中数据;由多名观察者按照系统评价和荟萃分析优先报告条目(PRISMA)指南进行。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于发病24小时内、NIHSS≤5分的轻型卒中患者,若未排除CYP2C19功能缺失等位基因,作者认为阿司匹林联合替格瑞洛成为最优治疗的概率更高(SUCRA 0.94)。
- 对于TIA患者,阿司匹林联合替格瑞洛相对于阿司匹林联合氯吡格雷的优越性未被证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Dual antiplatelet therapy (DAPT) appears to be an effective treatment option for minor (nondisabling) acute ischemic stroke. This conclusion is based on trials that include both transient ischemic attack (TIA) and minor stroke; however, these 2 conditions may differ.
OBJECTIVE: To compare DAPT regimens specifically for minor stroke.
DATA SOURCES: PubMed was searched for randomized clinical trials published up to November 4, 2023. Search terms strategy included TIA, transient ischemic attack, minor stroke, or moderate stroke, with the filter randomized controlled trial. Unpublished data on minor stroke were sourced from authors and/or institutions.
STUDY SELECTION: Trials testing DAPT within the first 24 hours of a minor stroke (defined as a National Institutes of Health Stroke Scale score ≤5) were included by consensus. Of 1508 studies screened, 6 (0.3%) initially met inclusion criteria and were reviewed.
DATA EXTRACTION AND SYNTHESIS: The study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by multiple observers. Bayesian fixed-effect network meta-analysis was conducted. Secondary analysis performed for high-risk TIA alone.
MAIN OUTCOMES AND MEASURES: Treatments were ranked using a probability measure called surface under the cumulative rank curve (SUCRA). The primary outcome was subsequent ischemic stroke at 90 days. Secondary outcomes included major hemorrhage, mortality, and hemorrhagic stroke. The number needed to treat (NNT) and number needed to harm (NNH) were obtained.
RESULTS: Five trials were included that described 28 148 patients, of whom 22 203 (78.9%) had a minor stroke. Of these, 13 995 (63.0%) were in DAPT groups and 8208 (37.0%) in aspirin (acetylsalicylic acid) groups. Aspirin and ticagrelor had a 94% probability of being the superior treatment for minor stroke (SUCRA, 0.94) for the primary outcome. Both aspirin and ticagrelor (NNT, 40; 95% CI, 31-64) and aspirin and clopidogrel (NNT, 58; 95% CI, 39-136) were superior to aspirin alone in the prevention of recurrent ischemic stroke at 90 days. Both treatments had higher rates of major hemorrhage than aspirin alone (NNH for aspirin and ticagrelor, 284; 95% CI, 108-1715 vs NNH for aspirin and clopidogrel, 330; 95% CI, 118-3430), but neither had increased risk of hemorrhagic stroke or death. For high-risk TIA, ticagrelor and aspirin had a 60% probability (SUCRA, 0.60) and clopidogrel and aspirin had a 40% probability (SUCRA 0.40) of being a superior treatment; neither was optimum, but both were superior to aspirin alone for the primary outcome.
CONCLUSIONS AND RELEVANCE: These findings suggest that DAPT with aspirin and ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles has not been excluded. For patients with TIA, the superiority of aspirin and ticagrelor vs aspirin and clopidogrel was not demonstrated.
参考来源
- Lim A, Ma H, Ly J, et al. Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: A Bayesian Network Meta-Analysis. JAMA Netw Open. 2024. PMID: 38753327. doi:10.1001/jamanetworkopen.2024.11735
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。